Poland· PL-100362830
Imlygic
A talimogene laherparepvec product containing talimogeni laherparepwecum, registered in Poland by Amgen Europe B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Talimogene laherparepvec is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XL02 (talimogene laherparepvec), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Talimogene laherparepvec · ATC L01XL02
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Talimogeni laherparepwecum
- Manufacturer
- Amgen Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01XL02
- ATC class
- Talimogene laherparepvec
- Defined daily dose
- 0.14 DE, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991259495
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
289 interactions on record for talimogene laherparepvec.
Graded by severity as the source publishes them — 284 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Talimogene laherparepvec · interactions on record
289 records
- 284 severe
- 5 moderate
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XL02
Talimogene laherparepvec, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/046cdb09-89a6-4967-9441-5bfddc41bece GET /v1/drugs/046cdb09-89a6-4967-9441-5bfddc41bece?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "10^6 jednostek określających miano wirusa (PFU)/ml",
"packaging": "05909991259495 ¦ Rpz ¦ EU/1/15/1064/001 ¦ 113822\n1 fiol. 1 ml",
"substance": "Talimogeni laherparepwecum 10^6 jednostek określających miano wirusa (PFU)/ml",
"common_name": "Talimogeni laherparepwecum",
"pl_product_id": "100362830",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about talimogene laherparepvec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.